Uniseed is a venture fund operating at the Universities of Melbourne, Queensland and New South Wales, with investment capital provided by the three universities and AustralianSuper – a leading industry superannuation fund. Uniseed’s mandate is to facilitate the commercialisation of university-generated intellectual property by targeted investment in highly promising technologies.
Uniseed’s investments cover a range of technology sectors. To date, the fund has exited four investments through trade sales; a neuropathic pain drug (Spinifex), a drug in development to treat fibrosis (Fibrotech), an IT security technology (Vintela) and a semi-conductor technology (Fultec). Its biotechnology portfolio is maturing, with Hatchtech completing a pivotal Phase 3 trial for its human head lice treatment in 2014. Other companies have products on the market (Hydrexia, Progel, BT Imaging, Smart Sparrow) or are collaborating with leading global companies in the respective field.